Ankit Mahadevia
2019
In 2019, Ankit Mahadevia earned a total compensation of $1.8M as Chief Executive Officer at Spero Therapeutics, a 148% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $250,000 |
|---|---|
| Option Awards | $752,778 |
| Salary | $497,083 |
| Stock Awards | $285,023 |
| Other | $792 |
| Total | $1,785,676 |
Mahadevia received $752.8K in option awards, accounting for 42% of the total pay in 2019.
Mahadevia also received $250K in non-equity incentive plan, $497.1K in salary, $285K in stock awards and $792 in other compensation.
Rankings
In 2019, Ankit Mahadevia's compensation ranked 6,484th out of 13,971 executives tracked by ExecPay. In other words, Mahadevia earned more than 53.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,484 out of 13,971 | 54th |
Division Manufacturing | 2,458 out of 5,695 | 57th |
Major group Chemicals And Allied Products | 896 out of 2,194 | 59th |
Industry group Drugs | 760 out of 1,880 | 60th |
Industry Pharmaceutical Preparations | 557 out of 1,392 | 60th |
Source: SEC filing on September 30, 2020.
Mahadevia's colleagues
We found two more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2019.
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019